Alnylam Pharmaceuticals ALNY Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $205.99M+84.7% | $111.54M-55.6% | $251.08M+479% | -$66.28M-263% | -$18.25M+78.2% | ||
| $13.55M+0.3% | $13.51M-2.2% | $13.8M-1.0% | $13.94M-3.2% | $14.41M+1.7% | ||
| $70.15M-2.1% | $71.63M-33.8% | $108.21M-3.1% | $111.68M+96.9% | $56.71M-38.1% | ||
| $110.42M— | —— | $399.86M+192% | $136.91M+1,742% | $7.43M-87.5% | ||
| $3.32M— | —— | -$4.98M+55.3% | -$11.14M-79.3% | -$6.22M-632% | ||
| -$176.03M— | —— | $223.51M+21.4% | $184.15M+217% | -$157.74M— | ||
| $6.32M-91.1% | $70.99M+242% | $20.74M— | $0-100% | $32.77M+230% | ||
| $2.99M— | —— | —— | -$18.51M+4.4% | -$19.35M-186% | ||
| -$1.63M— | $0+100% | -$12.54M+4.1% | -$13.08M+52.1% | -$27.32M-113% | ||
| $0— | —— | —— | -$1.35M-41.2% | -$956K-476% | ||
| $70.5M-56.9% | $163.56M-49.7% | $325.11M+109% | $155.73M+229% | -$120.31M-27.1% | ||
| $21.83M-6.3% | $23.29M+91.8% | $12.14M-15.0% | $14.29M+59.3% | $8.97M-1.4% | ||
| $261.63M+10.9% | $235.91M+13.4% | $207.97M-54.7% | $459.56M+14.4% | $401.64M-17.5% | ||
| -$25.54M— | $0-100% | $501.11M+454% | -$141.38M-224% | $113.77M+315% | ||
| $13.16M-68.4% | $41.7M-46.4% | $77.74M-4.3% | $81.22M+64.5% | $49.37M+36.1% | ||
| -$9K— | —— | —— | —— | $0— | ||
| $15.71M— | —— | -$448.35M-966% | $51.76M+12.3% | $46.08M+48.7% | ||
| -$7.06M— | —— | —— | $27.51M+95.7% | $14.06M+181% | ||
| $53.61M-67.7% | $166.01M-56.0% | $376.94M+303% | $93.61M+74.7% | $53.6M— | ||
| $64.2M-43.3% | $113.32M+374% | $23.89M+90.1% | $12.57M-81.8% | $68.93M+459% | ||
| $2.37M— | —— | $1.28M— | —— | $2.97M-52.1% | ||
| $0— | —— | —— | -$1.35M-41.2% | -$956K-476% | ||
| $6.32M-91.1% | $70.99M+242% | $20.74M— | $0-100% | $32.77M+230% | ||
| —— | $59.6M0.0% | $59.6M0.0% | $59.6M0.0% | $59.6M+87.5% | ||
| $66.24M— | —— | $40.86M+143% | $16.81M-69.2% | $54.63M+54.7% | ||
| $48.83M— | $0-100% | $1.7M-81.6% | $9.25M-81.1% | $48.83M— | ||
| $13.16M-68.4% | $41.7M-46.4% | $77.74M-4.3% | $81.22M+64.5% | $49.37M+36.1% | ||
| —— | $1.5M0.0% | $1.5M0.0% | $1.5M0.0% | $1.5M— | ||
| -$9K— | —— | —— | —— | $0— | ||
| $6M— | —— | —— | —— | $0— | ||
| $3.43M— | —— | —— | —— | $3.28M— | ||
| $4.1M— | $0-100% | $1.7M-81.6% | $9.25M-81.1% | $48.83M— | ||
| $0-100% | $8.82M+129% | $3.84M— | $0-100% | $9.83M— | ||
| $2.37M— | —— | $1.28M— | —— | $2.97M-52.1% | ||
| $48.67M-65.3% | $140.26M-55.2% | $312.97M+121% | $141.44M+209% | -$129.28M-24.6% | ||
| $48.67M-65.3% | $140.26M-55.2% | $312.97M+121% | $141.44M+209% | -$129.28M-24.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Alnylam Pharmaceuticals generate?
- Alnylam Pharmaceuticals (ALNY) generated $714.9M in operating cash flow over the trailing twelve months.
- What is Alnylam Pharmaceuticals's free cash flow?
- After $71.6M of capital expenditures, Alnylam Pharmaceuticals's free cash flow was $643.3M over the trailing twelve months, up 931.4% year over year.
- Where does Alnylam Pharmaceuticals's cash flow data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
